IsoPET® Therapy | patient expression of interest

IsoPet® is now commercially available as part of a company-sponsored program to gain experience on the use of the product and to share the results of this therapy with the veterinary community. Interested pet owners should send this completed form to mkorenko@radiogel.com.

Vista Veterinary Hospital will review the information and provide their recommendation regarding applicability of IsoPet® therapy.

Pet Owner Details:

Pet Parent Name

Cell Phone Number

Address

CIty | State | Zip

Pet Details:

Pet Name

Pet Breed

Pet Age

Pet Approximate Weight

General Health

Health issues other than the tumor

Tumor Details:

Approximate Shape

Approximate Diameter

Tumor Location

Tumor Type (if known)

Slow or fast growing – e.g. Approximate length of time since first observed

Recurring tumor?

Previous Tumor Therapies (if selected, medical records will be requested).

I understand the above details and consent to be contacted to determine further eligibility

Please enter the code:

The Privacy Policy applies.

Note: Please fill out the fields marked with an asterisk.

General Understanding:

You will be participating in a developmental therapy. The therapy has demonstrated limited, but positive results. The data from the tests will be made available to Vivos Inc. and other clinics and could be included in published paper or conferences. Since it is developmental the pet owner recognizes there are risks.

IsoPET® therapy price is competitive with the cost of external beam therapy.

CURRENT RELEASE

Vivos Inc. Announces Listing to the OTCQB

Richland WA, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc. a company engaged in the development and commercialization of minimally invasive brachytherapy treatments to combat cancer in animals and humans, today announced that its common shares have been approved for trading on the OTCQB Marketplace (OTCQB) under the symbol “RDGL” effective as of the open of trading today.

"The listing of our common stock to the OTCQB Exchange is an important milestone for Vivos Inc," said Mike Korenko Vivos Inc CEO. “We look forward to continuing to increase the visibility of Vivos Inc. and believe that the broader exposure afforded by the OTCQB is another important step in that process. We are working diligently to increase the investment community’s awareness of Vivos Inc. as part of our larger mandate to inform the veterinary and medical community about Isopet® and Radiogel™.”

The OTCQB is a venture market operated by OTC Markets Group and designed for early-stage and developing US and international companies. To be eligible, companies must be current in their reporting and undergo an annual verification and management certification process. To learn more, visit otcmarkets.com.

About Vivos Inc. (OTCQB:RDGL) >> Read Full Release

PRESS RELEASES

Click here for more news and updates

Stock Quote

Links

VIVOS Inc. (OTCQB: RDGL)
719 Jadwin Avenue. Richland, Washington 99352 US
T: 509.736.4000 E: mkorenko@radiogel.com